← Russell 3000 cross-section

AIRS Airsculpt Technologies, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$202m
Revenue TTM
$151m
Net income TTM
$-12m
Free cash flow
$1m
Composite score
37.2
Sector rank
#2864

Valuation

P / E
EV / EBITDA
EV / sales
1.4
FCF yield
0.38%
Earnings yield vs 10-yr
-10.54pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7.8%
EBITDA margin
-0.2%
ROE
-11.2%
ROIC
-10.6%
Revenue growth
-8.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For the three and six months ended June 30, 2026, we generated approximately $42.9 million and $82.3 million of revenue, respectively, compared to $44.0 million and $83.4 million for the three and six months ended June 30, 2025, respectively. We evaluate our selling expense as compared to growth in our sales volume and will invest accordingly to the extent we believe we can position ourselves for future growth without materially negatively impacting our Adjusted EBITDA Margins. The table also shows the percentage relationship to revenue for the periods indicated: Revenue— Our revenue decreased $1.1 million, or 2.5%, compared to the same period in 2025. …Airsculpt Technologies, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →